Sign In
Buy ADAP
$0.0549
+0 (+0%)
At Close: Feb 20, 2026
The positioning of the Global T-Cell Immunotherapy Market vendors in FPNV Positioning Matrix are determined by Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel S
Adaptimmune Therapeutics (NASDAQ:ADAP) Earns Neutral Rating from Analysts at Mizuho
06:50am, Thursday, 23'rd Apr 2020
Equities research analysts at Mizuho began coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP) in a research note issued on Tuesday, MarketBeat reports. The brokerage set a “neutral” rati
BofA likes Johnson & Johnson in premarket analyst action
11:38am, Wednesday, 22'nd Apr 2020
Adaptimmune (NASDAQ:ADAP) initiated with Neutral rating and $3 (17% downside risk) price target at Mizuho Securities.Autolus Therapeutics (NASDAQ:AUTL) initiated with Buy rating and $18 (90% upside) p
Adaptimmune Therapeutics (ADAP) Initiated with a Hold at Mizuho Securities
08:16pm, Tuesday, 21'st Apr 2020
Mizuho Securities analyst Mara Goldstein initiated coverage with a Hold rating on Adaptimmune Therapeutics (ADAP) today and set a price target of $3.00.
Adaptimmune Therapeutics (ADAP) Initiated with a Hold at Mizuho Securities
08:16pm, Tuesday, 21'st Apr 2020
Mizuho Securities analyst
Mara Goldstein
initiated coverage with a
Hold
rating on Adaptimmune Therapeutics (
ADAP
–
Research Report
) today and set a price target of
$3.00
. The company’s shares c
Autolus Therapeutics (AUTL) Receives a New Rating from Mizuho Securities
08:16pm, Tuesday, 21'st Apr 2020
In a report released today, Mara Goldstein from Mizuho Securities initiated coverage with a Buy rating on Autolus Therapeutics (AUTL) and a price target
Autolus Therapeutics (AUTL) Receives a New Rating from Mizuho Securities
08:16pm, Tuesday, 21'st Apr 2020
In a report released today, Mara Goldstein from Mizuho Securities initiated coverage with a Buy rating on Autolus Therapeutics (AUTL
Mizuho Securities Initiates a Buy Rating on Iovance Biotherapeutics (IOVA)
08:16pm, Tuesday, 21'st Apr 2020
In a report released today, Mara Goldstein from Mizuho Securities initiated coverage with a Buy rating on Iovance Biotherapeutics (IOVA) and a price
Mizuho Securities Initiates a Buy Rating on Iovance Biotherapeutics (IOVA)
08:16pm, Tuesday, 21'st Apr 2020
In a report released today,
Mara Goldstein
from Mizuho Securities initiated coverage with a
Buy
rating on Iovance Biotherapeutics (
IOVA
–
Research Report
) and a price target of
$61.00
. The compan
JonesTrading Keeps Their Buy Rating on Mirati Therapeutics (MRTX)
05:04pm, Monday, 20'th Apr 2020
JonesTrading analyst Soumit Roy reiterated a Buy rating on Mirati Therapeutics (MRTX) today and set a price target of $130.00. The company's shares closed
JonesTrading Keeps Their Buy Rating on Mirati Therapeutics (MRTX)
05:04pm, Monday, 20'th Apr 2020
JonesTrading analyst
Soumit Roy
reiterated a
Buy
rating on Mirati Therapeutics (
MRTX
–
Research Report
) today and set a price target of
$130.00
. The company’s shares closed last Monday at $93.7
Adaptimmune Therapeutics PLC - (NASDAQ:ADAP) Given Consensus Recommendation of "Buy" by Analysts
07:04am, Sunday, 19'th Apr 2020
Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) has been given a consensus rating of “Buy” by the nine brokerages that are currently covering the firm, MarketBeat Ratings reports. Three analysts ha
Adaptimmune Therapeutics PLC - (NASDAQ:ADAP) Short Interest Up 70.5% in March
06:28am, Friday, 17'th Apr 2020
Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) was the target of a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 708,600 shares,
JonesTrading Sticks to Their Buy Rating for Surface Oncology (SURF)
04:53pm, Thursday, 16'th Apr 2020
In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Surface Oncology (SURF), with a price target of $12.00. The company's
JonesTrading Sticks to Their Buy Rating for Surface Oncology (SURF)
04:53pm, Thursday, 16'th Apr 2020
In a report released today,
Soumit Roy
from JonesTrading reiterated a
Buy
rating on Surface Oncology (
SURF
–
Research Report
), with a price target of
$12.00
. The company’s shares closed last Th
